These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16171052)

  • 21. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
    Kadoglou NP; Iliadis F; Liapis CD; Perrea D; Angelopoulou N; Alevizos M
    Diabetes Care; 2007 Sep; 30(9):2242-4. PubMed ID: 17586747
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular effects of the thiazolidinediones.
    Qayyum R; Schulman P
    Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
    MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700
    [No Abstract]   [Full Text] [Related]  

  • 26. [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].
    Olsovský J
    Vnitr Lek; 2005 Dec; 51(12):1412. PubMed ID: 16430111
    [No Abstract]   [Full Text] [Related]  

  • 27. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
    Vaccaro O; Riccardi G
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
    [No Abstract]   [Full Text] [Related]  

  • 28. [Rosiglitazone--statistics for benefits and problems].
    Hjelmesaeth J; Røislien J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
    [No Abstract]   [Full Text] [Related]  

  • 29. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 32. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 33. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 34. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
    Håkansson J
    Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
    [No Abstract]   [Full Text] [Related]  

  • 35. Failure to control risk factors among patients with type 2 diabetes; experience from a Greek cohort.
    Kollias A; Bliziotis IA; Xilomenos A; Tolis A
    Prim Care Diabetes; 2009 Nov; 3(4):249-52. PubMed ID: 19720571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.
    Uwaifo GI; Ratner RE
    Am J Cardiol; 2007 Feb; 99(4A):51B-67B. PubMed ID: 17307058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of the DREAM Study.
    Davidson MB
    Diabetes Care; 2007 Feb; 30(2):418-20. PubMed ID: 17259522
    [No Abstract]   [Full Text] [Related]  

  • 38. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risk in women with polycystic ovary syndrome.
    Cho LW; Atkin SL
    Minerva Endocrinol; 2007 Dec; 32(4):263-73. PubMed ID: 18091663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Type 2 diabetes mellitus and cardiovascular diseases: evaluation, treatment and prevention strategies].
    Mosseri MM; Fisman EZ; Tenenbaum A
    Harefuah; 2006 Feb; 145(2):141-6, 164. PubMed ID: 16509421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.